CHIMES Study

CHIMES is a multicenter, placebo-controlled, double-blind, parallel groups, phase III investigator initiated study recruiting 1,100 subjects.

The objective of the study is to measure the efficacy of NeuroAiD™ when initiated within the first forty-eight hours in post-stroke recovery. CHIMES is conducted by neurologists and uses standard neurologist efficacy endpoint, i.e., Modified Rankin Scale, NIHSS, Barthel index and Mini Mental State Examination.

This multicenter trial is currently being conducted in the Asia Pacific region, including the Republic of Singapore (National University Hospital, Singapore General Hospital, National Neuroscience Institute Tan Tock Seng and Changi General Hospital), and in the Philippines (University of Santo Tomas, Davao Medical Centre, and Jose Reyes) with the participation of international experts from France and Australia sitting in the Data Safety Monitoring Board. In Singapore, this study is fully sponsored and supported by the National Medical Research Council (NMRC) Ministry of Health.

CHIMES is headed by internationally renowned clinicians, including Professor Marie-Germaine Bousser, Hôpital Lariboisière, Paris, France; Professor Geoffrey Donnan, National Stroke Institute University of Melbourne, Australia; Professor David Machin Cteru, Singapore; and Professor Christophe Tzourio, Paris, France.

More details on the CHIMES study can be found at www.clinicaltrials.gov (identifier NCT00554723) and on the CHIMES Society website at www.chimes-society.org

Pharmacological Study

The study on the mechanism of action is led by Professor Lazdunski, a world-renowned scientist recognized for his contributions to research in pharmacology and pathology. This study was carried out in the CNRS Institute of Molecular and Cell Pharmacology in Sophia Antipolis, France. Initial studies demonstrated evidence of a NeuroAiD™ effect on neuroprotection and in neuronal connectivity. Further studies are ongoing to replicate the results and to investigate the potential effect of NeuroAiD™ on neuroregeneration.

Email Print PDF